A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors
TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous T cells are engineered to express a T cell receptor that recognizes tumor-associated antigens presented on specific Human Leukocyte Antigen (HLA) molecules. The purpose of this screening study is to collect samples to conduct HLA genotyping, HLA Loss of Heterozygosity (LOH) assessment, and expression of Tumor-associated Antigens (TAA) testing. These results will be used to determine if participants meet the eligibility criteria for these parameters and could potentially be enrolled in a TScan clinical study.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
The study team can explain what participation involves.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Nov 17, 2025 · Source: ClinicalTrials.gov
The study is underway but is not accepting new participants.
Observational
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- TScan Therapeutics, Inc.
- Interventions being studied
- Diagnostic Test: Tumor and HLA Profiling
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
- Willing and able to provide written informed consent.
- Male or female aged ≥18 years at the time of signing the informed consent.
- Have one of the following histologically or cytologically confirmed locally advanced (unresectable) or metastatic solid tumor for which the Sponsor has an associated clinical study:
- Head and neck cancer
- Cervical cancer
- Non-small cell lung cancer
- HPV positive anogenital cancers
- Sarcoma
- Other cancers with a reasonable likelihood of expressing 1 or more antigens included in a TScan clinical trial, following approval by the TScan Medical Monitor or their delegate.
- Willing to provide a buccal swab for HLA testing
- Willing to provide a saliva sample to use as a normal control for the LOH assay
- Have access to an adequate FFPE tumor block that is \<8 months old or is willing to provide a fresh core-needle biopsy from a location deemed safe by the treating medical team.
Participants undergoing anticancer therapy with curative intent such as tumor surgical resection with or without neoadjuvant/adjuvant therapy, or definitive chemoradiation, unless they have locoregionally advanced disease and are expected to have a high risk of relapse after their curative intent therapy as determined by the treating investigator.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- HonorHealth Research and Innovation InstituteScottsdale, Arizona
- University of California San DiegoSan Diego, California
- Yale Cancer CenterNew Haven, Connecticut
- Memorial Healthcare SystemHollywood, Florida
- University of Miami, Sylvester Comprehensive Cancer CenterMiami, Florida
- Orlando HealthOrlando, Florida
- University of South FloridaTampa, Florida
- University of ChicagoChicago, Illinois
- Norton Cancer InstituteLouisville, Kentucky
- Karmanos Cancer InstituteDetroit, Michigan
- University of Minnesota, Masonic Cancer CenterMinneapolis, Minnesota
- Columbia University Herbert Irving Comprehensive Cancer CenterNew York, New York
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Nov 17, 2025. Always confirm current availability with the study team.